Suchita Pakkala, MD, MS

• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

  • Phase

    III
  • Conditions

    Breast Cancer, Early Breast Cancer
  • Location

    Emory University Hospital Midtown, Grady Health System, Winship Cancer Institute

A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.

Clinical lung cancer

A Safety Analysis of Programmed Death 1 Pathway Inhibitors in Patients With Solid Tumor Malignancies and Preexisting Autoimmune Disease.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.

Journal for immunotherapy of cancer

Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation.

The oncologist

Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis.

The oncologist

Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database.

Clinical lung cancer

Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.

Head & neck

Personalized therapy for lung cancer: striking a moving target.

JCI insight

Immune checkpoint inhibitors in small cell lung cancer.

Journal of thoracic disease

Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.

Cancer

Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.

JAMA oncology

Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base.

Clinical lung cancer

Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm.

Hematology/oncology clinics of North America

Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer.

Journal of translational medicine

Adjuvant therapy for nonsmall cell lung cancer: recent advances and future perspectives.

Current opinion in oncology

Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia.

Cancer

Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy.

Cancer

Lung cancer in HIV-positive patients.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.

Clinical lung cancer

05/25/2025

Dr Pakala is very impressive overall. I wish she would provide more specific feedback to me on how my cancer is progressing and what the criteria for "being in remission" is. I will specifically ask her next visit.

04/30/2025

Dr Pakala made me very comfortable

04/23/2025

Dr Pakkala was better than very good. She was excellent!

04/16/2025

This was my first visit and I felt heard and supported

04/06/2025

All my experiences with Dr.Pakkula today were outstanding! I've never had a Dr that demonstrated so much care and concern for my treatment plan and health habits. Her initial exam was thorough, and she explained each phase of my treatment plan. I am so grateful for Dr. Pakkula's expertise and care on this initial visit!

03/26/2025

No bad experience.

03/12/2025

Excellent experience

02/26/2025

I was very impressed by the doctor. My visit was for a second opinion. Not only did she listen to me, she thoroughly explained her thoughts on the available treatment options along with their risks and benefits. She took my concerns about side effects seriously and offered advice on managing them. Although, my treatment plan did not change, I have a much clearer understanding of my risk profile and why it's needed, so much so that I will be moving my care to Emory despite a much longer drive.

02/23/2025

I really appreciate Dr Pakkala's patience and thoroughness in her patient consults.

01/31/2025

Very good experience

12/23/2024

Dr, Pakkala was very patient with my questions, slowly and carefully explained my condition in plain language, the available treatments, survival rates, associated conditions, and the drugs to be used in my treatment. She seemed to be well up on the latest research, and arranged for me to get economic help with my anti-cancer drugs.

12/11/2024

Dr Pakkala was very knowledgeable and helpful in explaining my symptoms for me to understand my condition.

12/07/2024

Detailed explanation for my treatment plan

10/25/2024

excellent service

07/04/2024

Good experience